Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a... (Publications)
Despite the availability of effective combined antiretroviral treatment, many patients still present with advanced HIV infection, often accompanied by an AIDS-defining disease. A subgroup of patients
Clinical value of the cultural formulation interview in Pune, India (Publications)
CONTEXT: Development of the cultural formulation interview (CFI) in DSM-5 required validation for cross-cultural and global use. AIMS: To assess the overall value (OV) of CFI in the domains of feasibi
Pharmacokinetics-pharmacodynamics analysis of spiroindolone analogs and KAE609 in a murine malaria model (Publications)
Limited information is available on pharmacokinetic and pharmacodynamic (PK-PD) parameters driving the efficacy of antimalarial drugs. Our objective was to determine dose response relationship of a pa
Travelers with immune-mediated inflammatory diseases: are they different? (Publications)
BACKGROUND: Patients with immune-mediated inflammatory diseases (IMIDs) increasingly benefit from improved health due to new therapeutic regimens allowing increasing numbers of such patients to travel
In Tanzania, the many costs of pay-for-performance leave open to debate whether the strategy is cost-effective (Publications)
Pay-for-performance programs in health care are widespread in low- and middle-income countries. However, there are no studies of these programs' costs or cost-effectiveness. We conducted a cost-effect
Activities of N,N' -diarylurea MMV665852 analogs against <em>Schistosoma mansoni</em> (Publications)
There is an unmet need to discover and develop novel antischistosomal drugs. As exemplified by MMV665852, N,N'-diarylureas have recently emerged as a promising antischistosomal chemotype. In this stud
Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis (Publications)
It has been suggested that initiatives to eradicate specific communicable diseases need to be informed by eradication investment cases to assess the feasibility, costs, and consequences of eradication